Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has shown positive results consistent with previously published evidence. Read more
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis treatment among neovascular age-related macular degeneration (AMD) patients. Read more
O=MEGA PREVIEW: Menicon Australia will be introducing the newest addition to the Miru family of contact lenses.The company will launch Miru 1day UpSide, the first and only silicone hydrogel daily disposable contact lens incorporated with the manufacturer’s Smart Touch technology. Read more
O=MEGA PREVIEW: Good Optical Services will display NuLids, a simple at-home dry eye treatment, as well as a new Sterileyes antibacterial feature for the Eye Doctor Hot & Cold Eye Compress product. Read more
A new research project examining the proteins that circulate in the eye’s fluids has the potential to pave the way for a test to diagnose glaucoma that doesn’t rely on intraocular pressure.
ASX-listed medical device company Visioneering Technologies (VTI) is aiming to raise up to $11.1 million in new capital after securing fresh commitments from lead investors.
US biomedical researchers have developed a self-clearing glaucoma drainage device that uses vibration technology to disperse harmful micro-organisms. Read more